CSF3 and neutropenia: Of note, several studies have reported that chemotherapy-induced neutropenia with TAS-102 (with or without bevacizumab) is associated with improved survival outcomes22–24, which highlights the importance of G-CSF prophylaxis to prevent or manage neutropenia and allow for continued TAS-102 plus bevacizumab treatment without the need for dose reduction.